| Contract Development and Manufacturing Organization (CDMO) | End-to-end pharma services including API and formulation development, clinical and commercial manufacturing. | Regulatory quality leadership, multi-site global footprint, strong customer relationships. | Mostly B2B serving global pharma and biotech companies. | Highly potent APIs, antibody drug conjugates, sterile injectables. | 3237 | 45 | Contract manufacturing and development fees from global pharma and biotech clients. | Project-based contracts with milestone payments and volume-based manufacturing revenues. | Biopharma funding recovery, innovation in complex molecules, US facility expansion. | Integrated CDMO portfolio with niche areas like HPAPI, ADCs, sterile injectables. |
| Complex Hospital Generics (CHG) | Complex hospital generic products in anesthesia, pain management, and injectables. | Market leader positions, manufacturing integration, regulatory approvals. | Hospitals, healthcare providers; B2B model. | Specialty sterile injectables and branded hospital generics. | 1948 | 27 | Product sales in US, Europe and emerging markets. | Direct sales with long-term contracts and market share-based revenues. | Market leadership in US generics, new product acquisitions, and geographic expansion. | Sevoflurane (inhalation anesthesia), Intrathecal Baclofen, Kenalog® (injectable corticosteroid). |
| Consumer Healthcare (PCH) | Over-the-counter consumer health and wellness products in skincare, analgesics, and cough. | Strong brand equity, large distribution network, rapid product innovation. | End consumers primarily in India; B2C model. | Power brands and e-commerce distribution channels. | 1093 | 15 | Retail sales through multi-channel distribution including e-commerce. | Direct to retailer and e-commerce sales; frequent new product launches. | Brand investments, e-commerce growth, new product launches. | Little’s, Lacto Calamine, CIR, i-range skincare brands. |
